Find Tolebrutinib manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

API Suppliers

API Suppliers

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 1971920-73-6, Prn2246, C]pyridin-2-one, Sar442168, Tolebrutinib [inn], Tolebrutinib [usan]
Molecular Formula
C26H25N5O3
Molecular Weight
455.5  g/mol
InChI Key
KOEUOFPEZFUWRF-LJQANCHMSA-N
FDA UNII
8CZ82ZYY9X

Tolebrutinib
Tolebrutinib is an orally bioavailable, brain-penetrant, selective, small molecule inhibitor of Bruton's tyrosine kinase (BTK), with potential immunomodulatory and anti-inflammatory activities. Upon oral administration, tolebrutinib is able to cross the blood-brain barrier and inhibits the activity of BTK both peripherally and in the central nervous system (CNS). This prevents the activation of the B-cell antigen receptor (BCR) signaling pathway, and the resulting immune activation and inflammation. The inhibition of BTK activity also prevents microglial inflammatory signaling in the CNS, and the resulting immune activation, neuroinflammation and neurodegeneration. BTK, a cytoplasmic tyrosine kinase and member of the Tec family of kinases, plays an important role in B lymphocyte development, activation, signaling, proliferation and survival. In addition to B cells, BTK is also expressed in innate immune cells, including macrophages and microglia, and plays an important role in the regulation of microglial inflammatory signaling.
1 2D Structure

Tolebrutinib

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
4-amino-3-(4-phenoxyphenyl)-1-[(3R)-1-prop-2-enoylpiperidin-3-yl]imidazo[4,5-c]pyridin-2-one
2.1.2 InChI
InChI=1S/C26H25N5O3/c1-2-23(32)29-16-6-7-19(17-29)30-22-14-15-28-25(27)24(22)31(26(30)33)18-10-12-21(13-11-18)34-20-8-4-3-5-9-20/h2-5,8-15,19H,1,6-7,16-17H2,(H2,27,28)/t19-/m1/s1
2.1.3 InChI Key
KOEUOFPEZFUWRF-LJQANCHMSA-N
2.1.4 Canonical SMILES
C=CC(=O)N1CCCC(C1)N2C3=C(C(=NC=C3)N)N(C2=O)C4=CC=C(C=C4)OC5=CC=CC=C5
2.1.5 Isomeric SMILES
C=CC(=O)N1CCC[C@H](C1)N2C3=C(C(=NC=C3)N)N(C2=O)C4=CC=C(C=C4)OC5=CC=CC=C5
2.2 Other Identifiers
2.2.1 UNII
8CZ82ZYY9X
2.3 Synonyms
2.3.1 Depositor-Supplied Synonyms

1. 1971920-73-6

2. Prn2246

3. C]pyridin-2-one

4. Sar442168

5. Tolebrutinib [inn]

6. Tolebrutinib [usan]

7. 8cz82zyy9x

8. Prn-2246

9. 4-amino-3-(4-phenoxyphenyl)-1-[(3r)-1-prop-2-enoylpiperidin-3-yl]imidazo[4,5-c]pyridin-2-one

10. (r)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-phenoxyphenyl)-1h-imidazo[4,5-c]pyridin-2(3h)-one

11. 4-amino-3-(4-phenoxyphenyl)-1-[(3r)-1-(prop-2-

12. Enoyl)piperidin-3-yl]-1,3-dihydro-2h-imidazo[4,5-

13. 2h-imidazo(4,5-c)pyridin-2-one, 4-amino-1,3-dihydro-1-((3r)-1-(1-oxo-2-propen-1-yl)-3-piperidinyl)-3-(4-phenoxyphenyl)-

14. 4-amino-1,3-dihydro-1-((3r)-1-(1-oxo-2-propen-1-yl)-3-piperidinyl)-3-(4-phenoxyphenyl)-2h-imidazo(4,5-c)pyridin-2-one

15. Unii-8cz82zyy9x

16. Tolebrutinib [who-dd]

17. Chembl4650323

18. Schembl18285621

19. Gtpl10625

20. Btk'168

21. Ex-a4699

22. Bdbm50557487

23. Who 11268

24. Sar-442168

25. Example 3 [wo2016196840a1]

26. Sar442168; Prn2246

27. Hy-109192

28. Cs-0119132

2.4 Create Date
2017-02-18
3 Chemical and Physical Properties
Molecular Weight 455.5 g/mol
Molecular Formula C26H25N5O3
XLogP33.2
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count5
Rotatable Bond Count5
Exact Mass455.19573968 g/mol
Monoisotopic Mass455.19573968 g/mol
Topological Polar Surface Area92 Ų
Heavy Atom Count34
Formal Charge0
Complexity749
Isotope Atom Count0
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1

Digital Content read-more

Create Content with PharmaCompass, ask us

STOCK RECAP #PipelineProspector

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty